Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Purple Biotech Ltd. PPBT
$1.87
+$0.03 (1.63%)
На 18:05, 12 мая 2023
+488.24%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
41836803.00000000
-
week52high
3.21
-
week52low
1.32
-
Revenue
-910000
-
P/E TTM
-2
-
Beta
1.34294300
-
EPS
-1.16000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 08 сент 2022 г. | |
| HC Wainwright & Co. | Buy | 17 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Purple Biotech to Present at the Jefferies London Healthcare Conference
GlobeNewsWire
03 ноя 2021 г. в 07:30
REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 12:20 pm GMT. The conference will take place from November 16 - 19, 2021. Management will be available for one-on-one meetings.
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
GlobeNewsWire
26 мая 2021 г. в 07:38
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST. The conference will take place from June 1 – June 4, 2021. Management will be available for one-on-one meetings.
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
GlobeNewsWire
20 мая 2021 г. в 07:00
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
GlobeNewsWire
19 мая 2021 г. в 07:00
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors.
Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
GlobeNewsWire
23 апр 2021 г. в 08:00
Preliminary Data from First Part of Study Anticipated in Second Half of 2021